Structural Basis of Splicing Modulation by Antitumor Macrolide Compounds

2018 | journal article. A publication with affiliation to the University of Göttingen.

Jump to: Cite & Linked | Documents & Media | Details | Version history

Cite this publication

​Structural Basis of Splicing Modulation by Antitumor Macrolide Compounds​
Cretu, C. ; Agrawal, A. A.; Cook, A.; Will, C. L.; Fekkes, P.; Smith, P. G. & Lührmann, R.  et al.​ (2018) 
Molecular Cell70(2) pp. 265​-273.e8​.​ DOI: https://doi.org/10.1016/j.molcel.2018.03.011 

Documents & Media

License

Published Version

GRO License GRO License

Details

Authors
Cretu, Constantin ; Agrawal, Anant A.; Cook, Andrew; Will, Cindy L.; Fekkes, Peter; Smith, Peter G.; Lührmann, Reinhard ; Larsen, Nicholas; Buonamici, Silvia; Pena, Vladimir
Abstract
SF3B is a multi-protein complex essential for branch site (BS) recognition and selection during pre-mRNA splicing. Several splicing modulators with antitumor activity bind SF3B and thereby modulate splicing. Here we report the crystal structure of a human SF3B core in complex with pladienolide B (PB), a macrocyclic splicing modulator and potent inhibitor of tumor cell proliferation. PB stalls SF3B in an open conformation by acting like a wedge within a hinge, modulating SF3B's transition to the closed conformation needed to form the BS adenosine-binding pocket and stably accommodate the BS/U2 duplex. This work explains the structural basis for the splicing modulation activity of PB and related compounds, and reveals key interactions between SF3B and a common pharmacophore, providing a framework for future structure-based drug design.
Issue Date
2018
Journal
Molecular Cell 
Organization
Max-Planck-Institut für biophysikalische Chemie 
ISSN
1097-2765
eISSN
1097-4164
Language
English

Reference

Citations


Social Media